Clinical trial NCT05379166: Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
Official title: Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Secondary Myelodysplastic Syndrome
Therapy-Related Myelodysplastic Syndrome
Lead sponsor: Ohio State University Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2022-05-18
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial studies the effect of venetoclax and azacitidine in treating patients with therapy related or secondary myelodysplastic syndrome. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax in combination with azacitidine may work better in treating patients with therapy related or secondary myelodysplastic syndrome.

Detailed description: PRIMARY OBJECTIVE:

I. Determine the proportion of participants that achieve a complete remission following treatment with azacitidine and venetoclax.

SECONDARY OBJECTIVES:

I. Assess safety of azacitidine and venetoclax combination therapy. II. Determine the overall response rate (ORR). III. Determine the complete cytogenetic response rate (CCyR). IV. Determine the duration of response (DOR). V. Estimate event-free survival (EFS). VI. Estimate overall survival (OS). VII. Determine combined hematologic improvement rate (HIR). VIII. Determine red blood cell transfusion independence rate. IX. Determine platelet transfusion independence rate. X. Determine proportion of participants whose disease transforms to acute myeloid leukemia (AML).

XI. Determine proportion of participants that proceed to allogeneic hematopoietic stem cell transplantation (alloHSCT).

XII. Compare response criteria between the 2006 International Working Group (IWG) and 2023 IWG criteria.

EXPLORATORY OBJECTIVES:

I. Determine baseline frequencies of cytogenetic aberrations and their relationships to response to study therapy.

II. Estimate progression-free survival (PFS). III. Obtain quality of life (QoL) information from patient-reported responses to Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a and European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - Core 30 (C30) questionnaires.

OUTLINE:

Patients receive venetoclax orally (PO) once daily (QD) on days 1-14 and azacitidine intravenously (IV) over 10-40 minutes on days 1-7 or days 1-5 of week 1 and days 1 and 2 of week 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and every 6 months for up to 24 months.

Eligibility criteria: Inclusion Criteria:

* Ability to understand and the willingness to sign a written informed consent document
* Age \>= 18 years at time of informed consent. Both men and women and members of all races and ethnic groups will be included
* Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
* Previously untreated therapy related myelodysplastic syndrome (t-MDS) with Revised International Prognostic Scoring System (IPSS-R) risk categories Intermediate, High or Very High (i.e., minimum IPSS-R score of 3.5) and presence of \< 20% bone marrow blasts per bone marrow biopsy/aspirate
* Patients with t-MDS which is defined as patients who have had prior anti-cancer therapy including chemotherapy and/or radiation therapy
* Aspartate aminotransferase (AST) \< 3.0 x upper limit of normal (ULN) x upper limit of normal (ULN; local laboratory)
* Alanine aminotransferase (ALT) \< 3.0 x ULN x ULN
* Total bilirubin =\< 2 x ULN (except for patients with known Gilbert's syndrome)
* Creatinine clearance \>= 30 mL/min OR serum creatinine \< 1.5 x the ULN
* White blood cell (WBC) count =\< 10,000/uL

  * Note: Treatment with hydroxyurea is permitted to lower the WBC to reach this inclusion criterion. The WBC should be determined \>= 24 hours after the last dose of hydroxyurea. The last dose of hydroxyurea should not be administered =\< 3 days prior to the first dose of azacitidine
* Females of childbearing potential (FOCBP) must agree to adequate contraception (1 form of contraception or abstinence) from the screening visit until 30 days following the last dose of venetoclax. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

  * FOCBP are those who have not been surgically sterilized or have not been free from menses for \> 1 year without an alternative medical cause
* Male patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from the screening visit until 90 days after the last dose of study treatment. They must also refrain from sperm donation from the screening visit until 90 days following the last dose of study treatment

Exclusion Criteria:

* Participant has received prior therapy with a venetoclax or other BH3 mimetic. Note: Prior supportive care in form of transfusions or growth factors, etc., is not considered prior therapy. Supportive care should be discontinued \>= 14 days prior to the first dose of study drug. Subjects may continue oral corticosteroids for management of conditions other than MDS (e.g., asthma, rheumatoid arthritis) at a stable daily dose equivalent to =\< 10 mg prednisone during screening and study participation
* Subject has a diagnosis other than previously untreated de novo MDS with IPSS-R risk categories Intermediate, High or Very High, including:

  * MDS with IPSS-R risk categories Very Low or Low (overall IPSS score \< 3)
  * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)
  * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN
* Patients who are suitable for and willing to receive intensive chemotherapy or eligible to proceed to allogeneic stem cell transplantation without additional therapy
* Known history of testing positive for Human Immunodeficiency Virus (HIV) infections, Hepatitis B, or Hepatitis C. For countries where HIV status is mandatory: testing positive for HIV during screening using a local test.
* Clinically significant ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure
* Patients with uncontrolled infection will not be enrolled until infection is treated and under control
* Hypersensitivity to any study agent when administered alone. Any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol
* Any psychiatric illness that prevents patient from informed consent process
* Pregnant of breastfeeding at the time of enrollment
* Subject has received allogeneic HSCT or solid organ transplantation
* Subject has a concurrent active malignancy requiring treatment or with an expected life expectancy less than 1 year with the exception of below. Any subject with a concurrent active malignancy will be reviewed by the PI for eligibility prior to enrollment

  * Adequately treated in situ carcinoma of the cervix uteri
  * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
  * Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy
* Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

  * Ongoing systemic infection (viral, bacterial, or fungal)
  * Acute pneumonia
  * Febrile neutropenia
* Subject has received strong or moderate CYP3A inducers within 7 days prior to the first dose of study drug
* Subject has received strong or moderate CYP3A inhibitors within 7 days prior to the first dose of study drug
* Subject has consumed one or more of the following within 3 days prior to the first dose of study drug:

  * Grapefruit or grapefruit products
  * Seville oranges (including marmalade containing Seville oranges)
  * Star fruit (carambola)
* Subject has a malabsorption syndrome or other condition that precludes an enteral route of administration
* Subject has history of a cardiovascular, endocrinologic, hepatic, immunologic metabolic, neurologic, psychiatric, pulmonary, renal disease, or any other condition that in the opinion of the investigator would adversely affect his/her participation in this study or interpretation of study results
* Subject has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug

Primary outcomes:
measure: Complete remission (CR)
timeFrame: At the end of Cycle 4 (each cycle is 28 days) or earlier based on bone marrow results
Secondary outcomes:
measure: Treatment emergent adverse events (AEs)
timeFrame: Up to 30 days after last dose of study drug
measure: Overall response rate (ORR)
timeFrame: At the end of the last cycle of study drug (each cycle is 28 days)
measure: Cytogenetic response rate (CCyR)
timeFrame: At the end of the last cycle of study drug (each cycle is 28 days)
measure: Overall survival (OS)
timeFrame: From date of death or the last known alive date for participants who withdraw from or complete the study without dying, assessed up to 24 months
measure: Duration of response (DOR)
timeFrame: From earliest occurrence of PR, mCR, or CR to onset of progressive disease, assessed up to 24 months
measure: Event free survival (EFS)
timeFrame: From event date or date of last clinic visit for participants without an event during the study period, assessed up to 24 months
measure: Hematologic improvement rate (HIR)
timeFrame: At the end of the last cycle of study drug (each cycle is 28 days)
measure: Rates of hematologic improvement-erythrocytes (HI-E)
timeFrame: At the end of the last cycle of study drug (each cycle is 28 days)
measure: Rates of hematologic improvement-platelets (HI-P)
timeFrame: At the end of the last cycle of study drug (each cycle is 28 days)
measure: Rates of hematologic improvement-neutrophils (HI-N)
timeFrame: At the end of the last cycle of study drug (each cycle is 28 days)
measure: Percentage of participants who have disease that transforms to acute myeloid leukemia (AML)
timeFrame: End of study follow-up period (24 months after last dose of study drug)
measure: Percentage of participants who proceed to allogeneic hematopoietic stem cell transplantation
timeFrame: 12 months after last dose of study drug
measure: Percentage of patients achieving CR, CR equivalent, CRi, CRh, PR, or HI
timeFrame: From first dose of study drug to end of last cycle of study drug (each cycle is 28 days)
Other outcomes:
measure: Detection of cytogenetic abnormalities
timeFrame: Up to 12 months or last bone marrow exam
measure: Biometric measures recorded by the FitBit (e.g., heart rate, number of steps taken, activity time, calories burned)
timeFrame: At the end of cycle 1 of study drug (each cycle is 28 days)
measure: Patient-reported outcomes (PROs)
timeFrame: Up to 12 months or end of treatment clinical visit
Locations:
city: Columbus
country: United States
facility: Ohio State University Comprehensive Cancer Center
state: Ohio
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
Study officials:
affiliation: Ohio State University Comprehensive Cancer Center
name: Uma M Borate, MD
role: PRINCIPAL_INVESTIGATOR
References: